Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tioconazole is a broad-spectrum imidazole antifungal agent primarily used to treat fungal and yeast infections. It is most commonly indicated for vulvovaginal candidiasis (vaginal yeast infections), but topical formulations are also used for dermatophyte infections such as ringworm (tinea corporis), jock itch (tinea cruris), athlete's foot (tinea pedis), tinea versicolor ("sun fungus"), and cutaneous candidiasis. Tioconazole acts by inhibiting 14-alpha demethylase, a cytochrome P-450 enzyme involved in converting lanosterol to ergosterol—an essential component of the fungal cell membrane. This inhibition disrupts ergosterol synthesis, increasing cellular permeability and leading to cell death. In addition to its antifungal activity against Candida species and other pathogenic yeasts and dermatophytes, tioconazole exhibits antibacterial effects on certain Gram-positive cocci bacteria[1][5][6]. It is available over-the-counter in various countries as single-dose vaginal ointments or topical creams.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tioconazole.